BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 30482592)

  • 1. In search of: Suggesting a course of action for the scientific community to research potential impacts of heritable gene editing on the maternal carrier.
    Gravelle R
    Semin Perinatol; 2018 Dec; 42(8):522-524. PubMed ID: 30482592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome engineering through CRISPR/Cas9 technology in the human germline and pluripotent stem cells.
    Vassena R; Heindryckx B; Peco R; Pennings G; Raya A; Sermon K; Veiga A
    Hum Reprod Update; 2016 Jun; 22(4):411-9. PubMed ID: 26932460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and application of CRISPR/Cas9 technologies in genomic editing.
    Zhang C; Quan R; Wang J
    Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of heritable diseases using CRISPR: Hopes, fears, and reality.
    Kofler N; Kraschel KL
    Semin Perinatol; 2018 Dec; 42(8):515-521. PubMed ID: 30420296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [CRISPR-Cas system as molecular scissors for gene therapy].
    Heinz GA; Mashreghi MF
    Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new era of gene editing for the treatment of human diseases.
    Kc M; Steer CJ
    Swiss Med Wkly; 2019 Jan; 149():w20021. PubMed ID: 30685869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advances in application of clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 system in stem cells research].
    Sun SJ; Huo JH; Geng ZJ; Sun XY; Fu XB
    Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):253-256. PubMed ID: 29690746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
    Kim EJ; Kang KH; Ju JH
    Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human germline editing in the era of CRISPR-Cas: risk and uncertainty, inter-generational responsibility, therapeutic legitimacy.
    Schleidgen S; Dederer HG; Sgodda S; Cravcisin S; Lüneburg L; Cantz T; Heinemann T
    BMC Med Ethics; 2020 Sep; 21(1):87. PubMed ID: 32912206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA Regulation of Clinical Applications of CRISPR-CAS Gene-Editing Technology.
    Grant EV
    Food Drug Law J; 2016; 71(4):608-33. PubMed ID: 29140647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome Editing: The Recent History and Perspective in Cardiovascular Diseases.
    Musunuru K
    J Am Coll Cardiol; 2017 Dec; 70(22):2808-2821. PubMed ID: 29191331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene editing in human development: ethical concerns and practical applications.
    Rossant J
    Development; 2018 Jul; 145(16):. PubMed ID: 30045910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of CRISPR/Cas Genome Editing Technology for Targeted Mutagenesis in Rice.
    Xu R; Wei P; Yang J
    Methods Mol Biol; 2017; 1498():33-40. PubMed ID: 27709567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.
    Chadwick AC; Musunuru K
    Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):12-18. PubMed ID: 28838920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR editing in biological and biomedical investigation.
    Huang J; Wang Y; Zhao J
    J Cell Physiol; 2018 May; 233(5):3875-3891. PubMed ID: 28786481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethics of Human Genome Editing.
    Coller BS
    Annu Rev Med; 2019 Jan; 70():289-305. PubMed ID: 30691366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
    Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
    Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off- and on-target effects of genome editing in mouse embryos.
    Ayabe S; Nakashima K; Yoshiki A
    J Reprod Dev; 2019 Feb; 65(1):1-5. PubMed ID: 30518723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Embryonic Regulation and Research: What Is the Status of Human Germline Genome Editing in Australia?
    Burbery R
    J Law Med; 2020 Apr; 27(3):718-740. PubMed ID: 32406632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.